Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2and CHA2DS2-VASc scores and arrhythmia recurrences

Heart

Volumn 101, Issue 2, 2015, Pages 126-131

  Kornej, Jelena ^a,b   Hindricks, Gerhard ^a   Banerjee, Amitava ^b   Arya, Arash ^a   Sommer, Philipp ^a   Rolf, Sascha ^a   Husser, Daniela ^a   Lip, Gregory Y H ^b   Bollmann, Andreas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CATHETER ABLATION; CAUCASIAN; CHA2DS2 VASC SCORE; CHADS2 SCORE; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; RECURRENT DISEASE; AGED; ATRIAL FIBRILLATION; DECISION SUPPORT SYSTEM; ELECTROCARDIOGRAPHY; GERMANY; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE; PROCEDURES; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; CATHETER ABLATION; DECISION SUPPORT TECHNIQUES; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; GERMANY; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RECURRENCE; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920508697     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2014-306013     Document Type: Article

References (29)

1. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
2. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009;119:1363-9.
3. Heeriga V, Conway DS, van der Kuip DA, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost 2006;4:1944-9.
4. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2011;123:2946-53.
5. Horio T, Iwashima Y, Kamide K, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010;28:1738-44.
6. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-35.
7. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7.
8. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009;20:705-11.
9. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010;159:1102-7.
10. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts. Circulation 2013;127:224-32.
11. Banerjee A, Fauchier L, Vourc'h P, et al. Renal impairment and ischaemic stroke risk assessment in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol 2013;61:2079-87.
12. Roldán V, Marín F, Manzano-Fernández S, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109:956-60.
13. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
14. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol 2006;48:2340-7.
15. Takahashi Y, Takahashi A, Kuwahara T, et al. Renal function after catheter ablation of atrial fibrillation. Circulation 2011;124:2380-7.
16. Roldan V, Marin F, Fernandez H, et al. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013;111:1159-64.
17. Schmidt M, Daccarett M, Rittger H, et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011;22:1092-8.
18. Berkowitsch A, Kuniss M, Greiss H, et al. Impact of impaired renal function and metabolic syndrome on the recurrence of atrial fibrillation after catheter ablation: a long term follow-up. Pacing Clin Electrophysiol 2012;35:532-43.
19. Chao TF, Lin YJ, Chang SL, et al. Associations between renal function, atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation. Circ J 2011;75:2326-32.
20. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
22. Eitel C, Hindricks G, Sommer P, et al. Circumferential pulmonary vein isolation and linear left atrial ablation as a single-catheter technique to achieve bidirectional conduction block: the pace-and-ablate approach. Heart Rhythm 2009;7:157-64.
23. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
24. Macias-Nunez J, Lopez-Novoa J. The aging kidney in health and disease. New York: Springer, 2008:93-112.
25. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985;33:278-85.
26. Rifkin DE, Shlipak MG, Katz R, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008;168:2212-18.
27. Olesen JB, Gislason GH, Torp-Pedersen C, et al. Atrial fibrillation and vascular disease - a bad combination. Clin Cardiol 2012;35:15-20.
28. Dinov B, Kosiuk J, Kircher S, et al. Impact of metabolic syndrome on left atrial electro-anatomical remodeling and outcomes after radiofrequency ablation of non valvular atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:483-9.
29. Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 2013;127:569-74.